The NOTION 2 Low-risk Trial in Younger Patients

The Evolut R Low-risk Trial

The PARTNER 3 Low-risk Trial

The UK All-comer TAVI Study

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing – TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Insights From the New 2017 ESC Valve Disease Guidelines: Changes in the Management of Aortic Stenosis

Take-home Messages for Managing Aortic Valve Disease From the 2017 AHA/ACC Focused Update

When is TAVR Indicated for Low Gradient AS With Preserved Ejection Fraction? Case Examples

How to Optimally Perform Valve-in-Valve Implantation in a Small Surgical Valve (Including Bioprosthetic Valve Fracture) – Case Examples